{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:20:47Z","timestamp":1781191247819,"version":"3.54.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"Aim of the study<\/jats:title>Tuberous sclerosis complex (TSC) is a genetic and multisystemic disorder that affects between 1\/6\u2019000 and 1\/10\u2019000 of newborns. Clinical criteria and\/or genetic analysis establish the diagnosis. The mechanistic target of rapamycin (mTOR) inhibitors everolimus or sirolimus reduce the severity of several TSC-related clinical traits. We report here on the epidemiology and management of TSC patients in a large Swiss canton: the canton of Vaud.<\/jats:p><\/jats:sec>Method<\/jats:title>We extracted patient files containing the diagnostic code TSC in 2015 at the Lausanne University hospital (tertiary reference center for a population of about 755\u2019000 people) and in specialized neurological institutions of the same region.<\/jats:p><\/jats:sec>Results<\/jats:title>We identified 52 patients with a diagnosis of TSC. The majority of the patients with a pathologic result in genetic testing were positive for a pathogenic variant in the TSC2<\/jats:italic> gene, including five cases of contiguous gene deletion syndrome of TSC2<\/jats:italic> and PKD1<\/jats:italic> causing both polycystic kidney disease and TSC. The most frequent clinical manifestations encountered were affecting the skin (87% of patients), the brain (83%), the heart (46%) and the kidneys (46%). Neuropsychiatric disorders were described in 56% of cases. At the time of data collection (2015), there were 2 patients using systemic mTOR inhibitors and 16 patients using topical mTOR inhibitors for dermatological features. Next, we compared this data with those of large published cohorts. While we found fewer cases than expected for the screened population, demographic as well as genetic data were overall similar to the literature. However, we observed that some clinical manifestations (renal, lung and neuropsychiatric disorders) were less frequently described in our cohort.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>This work indicates that TSC and some of its clinical manifestations is under-reported. It raises concern that patients with mild manifestations are often not referred to reference centers with dedicated multidisciplinary group. The follow-up by expert board is instrumental in offering systematic screening of all putatively affected organs and to assess the eligibility for targeted treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1513619","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T06:23:55Z","timestamp":1733984635000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Tuberous sclerosis: a survey in the canton of Vaud, Switzerland"],"prefix":"10.3389","volume":"11","author":[{"given":"Olivia","family":"Hagon-Nicod","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Fellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Novy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Lebon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Wider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Lazor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bonny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"ref1","year":""},{"key":"ref2","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.revmed.2021.03.003","article-title":"Scl\u00e9rose tub\u00e9reuse de Bourneville: mise au point","volume":"42","author":"Pfirmann","year":"2021","journal-title":"Rev M\u00e9decine Interne"},{"key":"ref3","article-title":"Tuberous sclerosis complex","volume-title":"GeneReviews\u00ae [Internet]","author":"Northrup","year":"1993"},{"key":"ref4","author":"Zamora","year":"2023"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1177\/088307389801301206","article-title":"Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria","volume":"13","author":"Roach","year":"1998","journal-title":"J Child Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","article-title":"International tuberous sclerosis complex consensus group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational tuberous sclerosis complex consensus conference","volume":"49","author":"Northrup","year":"2013","journal-title":"Pediatr Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pediatrneurol.2021.07.011","article-title":"Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations","volume":"123","author":"Northrup","year":"2021","journal-title":"Pediatr Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13023-016-0553-5","article-title":"TuberOus SClerosis registry to increase disease awareness (TOSCA) \u2013 baseline data on 2093 patients","volume":"12","author":"Kingswood","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1590\/abd1806-4841.20186972","article-title":"Tuberous sclerosis complex: review based on new diagnostic criteria*","volume":"93","author":"Portocarrero","year":"2018","journal-title":"An Bras Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2174\/157015912804499537","article-title":"mTOR inhibitors in tuberous sclerosis complex","volume":"10","author":"Curatolo","year":"2012","journal-title":"Curr Neuropharmacol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13023-022-02266-0","article-title":"Perfect match: mTOR inhibitors and tuberous sclerosis complex","volume":"17","author":"Luo","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e0158476","DOI":"10.1371\/journal.pone.0158476","article-title":"Long-term use of Everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study","volume":"11","author":"Franz","year":"2016","journal-title":"PLoS One"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/ana.20784","article-title":"Rapamycin causes regression of astrocytomas in tuberous sclerosis complex","volume":"59","author":"Franz","year":"2006","journal-title":"Ann Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e0180939","DOI":"10.1371\/journal.pone.0180939","article-title":"Everolimus long-term use in patients with tuberous sclerosis complex: four-year update of the EXIST-2 study","volume":"12","author":"Bissler","year":"2017","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1111\/jdv.14964","article-title":"Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomized EXIST-1 and EXIST-2 studies","volume":"32","author":"Franz","year":"2018","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet Lond Engl"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1111\/epi.17099","article-title":"Adjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: results from the postextension phase of EXIST-3","volume":"62","author":"Franz","year":"2021","journal-title":"Epilepsia"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ejpn.2013.06.002","article-title":"Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?","volume":"17","author":"Wiegand","year":"2013","journal-title":"Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1183\/09031936.00210714","article-title":"Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study","volume":"46","author":"Goldberg","year":"2015","journal-title":"Eur Respir J"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"101310","DOI":"10.1016\/j.rmcr.2020.101310","article-title":"Effect of everolimus on multifocal micronodular pneumocyte hyperplasia in tuberous sclerosis complex","volume":"31","author":"Daccord","year":"2020","journal-title":"Respir Med Case Rep"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.pediatrneurol.2014.02.016","article-title":"Topical everolimus for facial angiofibromas in the tuberous sclerosis complex. A first case report","volume":"51","author":"Dill","year":"2014","journal-title":"Pediatr Neurol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/acn3.494","article-title":"Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders","volume":"4","author":"Krueger","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","article-title":"International tuberous sclerosis complex consensus group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 international tuberous sclerosis complex consensus conference","volume":"49","author":"Krueger","year":"2013","journal-title":"Pediatr Neurol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1542\/peds.2010-0192","article-title":"Tuberous sclerosis complex: diagnostic challenges, presenting symptoms, and commonly missed signs","volume":"127","author":"Staley","year":"2011","journal-title":"Pediatrics"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1177\/0883073807309250","article-title":"Clinical presentation and diagnosis of tuberous sclerosis complex in infancy","volume":"23","author":"Datta","year":"2008","journal-title":"J Child Neurol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13023-018-0870-y","article-title":"Incidence of tuberous sclerosis and age at first diagnosis: new data and emerging trends from a national, prospective surveillance study","volume":"13","author":"Ebrahimi-Fakhari","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"806","DOI":"10.7326\/0003-4819-154-12-201106210-00008","article-title":"Recognition of tuberous sclerosis in adult women: delayed presentation with life-threatening consequences","volume":"154","author":"Seibert","year":"2011","journal-title":"Ann Intern Med"},{"key":"ref30","first-page":"525","article-title":"Pulmonary lymphangioleiomyomatosis in a male patient with tuberous sclerosis complex","volume":"23","author":"Miyake","year":"2005","journal-title":"Radiat Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1053\/j.ajkd.2015.05.016","article-title":"Long-term follow-up assessing renal angiomyolipoma treatment patterns, morbidity, and mortality: an observational study in tuberous sclerosis complex patients in the Netherlands","volume":"66","author":"Eijkemans","year":"2015","journal-title":"Am J Kidney Dis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1513619\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T06:23:57Z","timestamp":1733984637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1513619\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":31,"alternative-id":["10.3389\/fmed.2024.1513619"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1513619","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,12]]},"article-number":"1513619"}}